BUDGET IMPACT OF ALBUMIN-BOUND PACLITAXEL plus GEMCITABINE IN THE TREATMENT OF METASTATIC PANCREATIC CANCER

被引：1
|
作者：
Binder, G. [1 ]
Whiting, S. [1 ]
Milentijevic, D. [2 ]
Penenberg, D. [3 ]
Wei, X. [3 ]
Kayitalire, L. [1 ]
Renschler, M. F. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
[2] Market Access Solut, Raritan, NJ USA
[3] Celgene Corp, Berkeley Hts, NJ USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.435
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN40
引用
收藏
页码：A74 / A74
页数：1
相关论文
共 50 条
  • [21] Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study
    Carrato, Alfredo
    Garcia, Pilar
    Lopez, Rafael
    Macarulla, Teresa
    Rivera, Fernando
    Sastre, Javier
    Gostkorzewicz, Joana
    Benedit, Patricia
    Perez-Alcantara, Ferran
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 579 - 589
  • [22] Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients
    Ueda, Rikako
    Yamamoto, Naho
    Hori, Yuki
    Yoshida, Kouji
    Ohtsubo, Koushiro
    Terashima, Takeshi
    Shimada, Tsutomu
    Sai, Yoshimichi
    JOURNAL OF PHARMACEUTICAL HEALTH CARE AND SCIENCES, 2022, 8 (01)
  • [23] Risk factors for interstitial lung disease induced by gemcitabine plus albumin-bound paclitaxel therapy in pancreatic ductal adenocarcinoma patients
    Rikako Ueda
    Naho Yamamoto
    Yuki Hori
    Kouji Yoshida
    Koushiro Ohtsubo
    Takeshi Terashima
    Tsutomu Shimada
    Yoshimichi Sai
    Journal of Pharmaceutical Health Care and Sciences, 8
  • [24] High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer
    Jameson, Gayle S.
    Borazanci, Erkut
    Poplin, Elizabeth
    Barrett, Michael T.
    Crowley, John
    Rosenthal, Adam
    Stoll-D'Astice, Amy
    AnsaIdo, Karen L.
    Boone, Steven
    Lebron, Leticia
    Ramanathan, Ramesh K.
    Kom, Ronald L.
    Von Hoff, Daniel D.
    CANCER RESEARCH, 2015, 75
  • [25] Nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreatic cancer: our experience
    Mare, M.
    Munao, S.
    Germana, S.
    Colarossi, C.
    Sciacca, D.
    Giuffrida, D.
    Giannone, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer A Phase 1b/2 Pilot Clinical Trial
    Jameson, Gayle S.
    Borazanci, Erkut
    Babiker, Hani M.
    Poplin, Elizabeth
    Niewiarowska, Anna A.
    Gordon, Michael S.
    Barrett, Michael T.
    Rosenthal, Adam
    Stoll-D'Astice, Amy
    Crowley, John
    Shemanski, Lynn
    Korn, Ron L.
    Ansaldo, Karen
    Lebron, Leticia
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    JAMA ONCOLOGY, 2020, 6 (01) : 125 - 132
  • [27] Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
    Wu, Jing
    Wang, Zheng
    Li, Jing
    Peng, Xue-Hui
    Tang, Yi-Chen
    Huang, Xiao-Bing
    He, Yong-Gang
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [28] Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
    Tian, Zhichao
    Zhang, Fan
    Li, Po
    Wang, Jiaqiang
    Yang, Jinpo
    Zhang, Peng
    Yao, Weitao
    Wang, Xin
    BMC CANCER, 2020, 20 (01)
  • [29] Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
    Zhichao Tian
    Fan Zhang
    Po Li
    Jiaqiang Wang
    Jinpo Yang
    Peng Zhang
    Weitao Yao
    Xin Wang
    BMC Cancer, 20
  • [30] Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer
    G. Roviello
    F. U. Conter
    E. Mini
    D. Generali
    M. Traversini
    D. Lavacchi
    S. Nobili
    N. Sobhani
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 669 - 677
12345